{
    "clinical_study": {
        "@rank": "6556", 
        "arm_group": {
            "arm_group_label": "group R", 
            "arm_group_type": "Experimental", 
            "description": "The starting dose of remifentanil is 0.5\u03bcg/kg and a step size was 0.05\u03bcg/kg."
        }, 
        "brief_summary": {
            "textblock": "This research attempts to find the optimum dose of remifentanil that can prevent the\n      unnecessary responses such as coughing, gagging, and movement when LMA is inserted during\n      sevoflurane induction in pediatric patients."
        }, 
        "brief_title": "the Effective Bolus Dose of Remifentanil for Laryngeal Mask Airway (LMA) Insertion in Children", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Respiratory Complication", 
        "detailed_description": {
            "textblock": "Anaesthesia is induced by inhalation with 3% sevoflurane. We control sevoflurane\n      concentration to maintain bispectral index (BIS) between 45~60 for 5 minutes. A\n      predetermined bolus dose of remifentanil is injected over 30 seconds. The LMA is attempted\n      60 seconds after bolus administration. The starting dose of remifentanil is 0.5\u03bcg/kg and a\n      step size is 0.05\u03bcg/kg. If LMA insertion is successful or failed in previous patient, an\n      decrement or increment of 0.05\u03bcg/kg remifentanil is injected to next patient, respectively."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  American Society of Anesthesiologists physical status 1 or 2\n\n          -  undergoing short elective surgery(i.e Strabismus surgery, Entropion surgery, Inguinal\n             hernia surgery, etc) under general anesthesia\n\n        Exclusion Criteria:\n\n          -  suspected difficult airways\n\n          -  respiratory disease (chronic obstructive pulmonary disease, upper respiratory\n             infection)\n\n          -  body mass index > 30 kg/m2\n\n          -  allergies to the study drugs\n\n          -  a history of gastric reflux"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919203", 
            "org_study_id": "apsj0723"
        }, 
        "intervention": {
            "arm_group_label": "group R", 
            "description": "The starting dose of remifentanil is 0.5\u03bcg/kg and a step size is 0.05\u03bcg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05\u03bcg/kg remifentanil is injected to next patient, respectively.", 
            "intervention_name": "Remifentanil", 
            "intervention_type": "Drug", 
            "other_name": "remifentanil (ultiva)"
        }, 
        "intervention_browse": {
            "mesh_term": "Remifentanil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 21, 2013", 
        "location": {
            "contact": {
                "email": "apsj0718@yu.ac.kr", 
                "last_name": "duckhee lee, M.D.", 
                "phone": "82-53-620-3365"
            }, 
            "facility": {
                "address": {
                    "city": "Nam gu", 
                    "country": "Korea, Republic of", 
                    "state": "Daegu", 
                    "zip": "705-035"
                }, 
                "name": "Department of Anesthesiology and Pain Medicine, Yeungnam University hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "the Effective Bolus Dose of Remifentanil for Laryngeal Mask Airway (LMA) Insertion in Pediatric Patients", 
        "overall_contact": {
            "email": "apsj0718@naver.com", 
            "last_name": "sangjin park, M.D.", 
            "phone": "82-53-620-3366"
        }, 
        "overall_official": {
            "affiliation": "Department of Anesthesiology and Pain Medicine, College of medicine, Yeungnam University, Daemyung-Dong, Nam-Gu, Daegu, Republic of Korea", 
            "last_name": "sangjin park, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Fail of LMA insertion is defined as body or limb movement, coughing or gagging with 2 minutes after LMA insertion, no proper jaw relaxation(difficult mouth opening), laryngospasm, bronchospasm, desaturation(SpO2<94%)", 
            "measure": "patients's response to the LMA insertion", 
            "safety_issue": "Yes", 
            "time_frame": "2 minutes after LMA insertion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919203"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yeungnam University College of Medicine", 
            "investigator_full_name": "Sangjin Park", 
            "investigator_title": "assistant professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Yeungnam University College of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sangjin Park", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}